Efficacy and safety of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib in relapsed or refractory chronic lymphocytic leukemia patients
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; JCAR 014
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 29 Jan 2019 New trial record
- 04 Dec 2018 Results assessing safety and efficacy of ibrutinib in relapsed or refractory patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.